Advertisement

Topics

Global Fibromyalgia Drugs Market 2015-2019

01:04 EDT 21 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Global Fibromyalgia Drugs Market 2015-2019 is a new report from Technavio published on 2015-07-14. This 73-page report is available in pdf from $2500.

About Fibromyalgia
According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms. Unlike arthritis, it does not cause joint, muscle or other tissue inflammation. However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue. Fibromyalgia affects women more than men. In the US, the condition affects more than 5 million people aged 18 years and above, of which 80-90% are women. There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.

Technavio's analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.

Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:
• Serotonin norepinephrine reuptake inhibitors
• GABA analogs
• Others

Technavio's report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

This report includes a discussion of the market in the following three regions:
• Americas: The major countries here are the US, Canada, Mexico, and Brazil
• EMEA: The major countries here are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: The major countries here are Japan, China, Australia, Singapore, South Korea, and India.

APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Actavis
• Eli Lilly
• Pfizer

Other Prominent Vendors
• Daiichi Sankyo
• Innovative Med Concepts
• Meda
• Meiji Seika
• Merck Sharp and Dohme
• Switch Biotech

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Savella
04.1.2 Cymbalta
04.1.3 Lyrica
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Signs and Symptoms
07.2.1 Pain and Muscle Stiffness
07.2.2 Sleep Disturbances
07.2.3 Fatigue
07.2.4 Chronic Headache
07.2.5 Other Symptoms
07.3 Epidemiology
07.4 Pathophysiology
07.5 Economic Burden
07.6 Novel Therapeutic Approach
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Fibromyalgia Drugs Market in US
08.3.1 Market Overview
08.3.2 Market Size and Forecast
08.4 Fibromyalgia Drugs Market in Europe
08.4.1 Market Overview
08.4.2 Market Size and Forecast
08.5 Five Forces Analysis
09. Market Segmentation by Chemical Class of Drug
09.1 Global Fibromyalgia Drugs Market by Chemical Class of Drug 2014-2019
09.2 Serotonin-norepinephrine Reuptake Inhibitors
09.3 GABA Analogs
09.4 Others
10. Geographical Segmentation
10.1 Global Fibromyalgia Drugs Market by Geography 2014-2019
11. Buying Criteria
12. Pipeline Portfolio
12.1 Key Information on Pipeline Candidates
12.1.1 TNX-102 SL
12.1.2 Lyrica CR
12.1.3 DS-5655
12.1.4 TD-9855
12.1.5 IMC-1
12.1.6 Mirtazapine
12.1.7 Flupirtine
12.1.8 SWT06101
12.1.9 ZYN001
13. Market Growth Drivers
14. Drivers and Their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and Their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Major Vendor Analysis 2014
19.2.1 Pfizer
19.2.2 Eli Lilly
19.2.3 Actavis
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Information
20.1.8 SWOT Analysis
20.2 Eli Lilly
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue
20.2.4 Sales by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Pfizer
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2014
20.3.4 Business Segmentation by Revenue 2013 and 2014
20.3.5 Geographical Segmentation by Revenue 2014
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis
21. Other Reports in This Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Epidemiology of Fibromyalgia 2014-2019
Exhibit 3: Pathophysiology of Fibromyalgia
Exhibit 4: Global Fibromyalgia Drugs Market 2014-2019 ($ millions)
Exhibit 5: Global Fibromyalgia Drugs Market: Key Takeaways
Exhibit 6: Fibromyalgia Drugs…

For more information open Global Fibromyalgia Drugs Market 2015-2019.

SKU: IRTNTR6480

Original Article: Global Fibromyalgia Drugs Market 2015-2019

NEXT ARTICLE

More From BioPortfolio on "Global Fibromyalgia Drugs Market 2015-2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Fibromyalgia
FMS (fibromyalgia syndrome) is a widespread idiopathic musculoskeletal pain and fatigue disorder, which is chronic. The pain comes from connective tissues, such as muscles, tendons, and ligaments, but not joints and patients describe it as an ache all ov...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...